Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 7:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Lines Skin Clear all
Completed Not applicable Interventional Accepts healthy volunteers

A Clinical Study Evaluating the Efficacy and Tolerability of a Topical Facial Treatment For Facial Rejuvenation

NCT06629792
View directory record Official record
Conditions
Fine Lines, Wrinkles, Laxity; Skin
Interventions
Gentle Cleanser, Facial Moisturizer, sunscreen SPF 30
Other
Lead sponsor
Revision Skincare
Industry
Eligibility
35 Years to 60 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Sep 20, 2026, 7:22 PM EDT
Completed Early Phase 1 Interventional

Phase 1 Study of ULSC in Patients With Polymyositis (PM) and Dermatomyositis (DM)

NCT04723303
View directory record Official record
Conditions
Polymyositis, Dermatomyositis
Interventions
Umbilical Cord Lining Stem Cells
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Sep 20, 2026, 7:22 PM EDT
Completed Phase 2 Interventional Results available

Abraxane, Avastin, and Gemcitabine as First-Line Therapy for Patients With Metastatic Breast Cancer

NCT00503906
View directory record Official record
Conditions
Breast Cancer
Interventions
Avastin, Gemcitabine, Abraxane
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Sep 20, 2026, 7:22 PM EDT
Terminated Phase 2 Interventional

A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer

NCT00607438
View directory record Official record
Conditions
Breast Cancer
Interventions
Paclitaxel Albumin Nanoparticle for Injectable Suspension (Abraxane), Sorafenib (Nexavar)
Drug
Lead sponsor
Veeda Oncology
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 10, 2012 · Synced Sep 20, 2026, 7:22 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma

NCT00924001
View directory record Official record
Conditions
Melanoma, Malignant Melanoma, Melanoma, Experimental
Interventions
DMF5 Melanoma Reactive TIL, Cyclophosphamide, Fludarabine, Aldesleukin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 24, 2012 · Synced Sep 20, 2026, 7:22 PM EDT
Completed Phase 2 Interventional

Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer

NCT00645177
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
ABT-869, paclitaxel, Placebo for ABT-869
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
San Francisco, California • Harvey, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 28, 2013 · Synced Sep 20, 2026, 7:22 PM EDT
Not listed Phase 2 Interventional

Tesetaxel as First-line Therapy for Metastatic Breast Cancer

NCT01221870
View directory record Official record
Conditions
Breast Neoplasm
Interventions
Tesetaxel once every 3 weeks, Tesetaxel once weekly
Drug
Lead sponsor
Genta Incorporated
Industry
Eligibility
18 Years and older · Female only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
4
States / cities
New York, New York • Greensboro, North Carolina • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2012 · Synced Sep 20, 2026, 7:22 PM EDT
Active, not recruiting Phase 2 Interventional

Efficacy and Safety of 500mg of Fulvestrant

NCT00585507
View directory record Official record
Conditions
Breast Cancer
Interventions
Fulvestrant
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2027
U.S. locations
5
States / cities
Boston, Massachusetts • Lowell, Massachusetts • South Weymouth, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 20, 2026, 7:22 PM EDT
Completed Not applicable Interventional

Aesthetic Outcome of Complex Linear Closure vs Second Intention Healing: Below the Knee

NCT05074212
View directory record Official record
Conditions
Wound Heal, Wound of Skin
Interventions
Factorial Assignment
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 20, 2026, 7:22 PM EDT
Completed Phase 2 Interventional Results available

Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer

NCT03414684
View directory record Official record
Conditions
Breast Cancer
Interventions
Carboplatin, Nivolumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
10
States / cities
Stamford, Connecticut • Bangor, Maine • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 20, 2026, 7:22 PM EDT
Terminated Phase 2 Interventional Results available

Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer

NCT00138125
View directory record Official record
Conditions
Breast Cancer
Interventions
Faslodex, Herceptin
Drug · Biological
Lead sponsor
Translational Oncology Research International
Other
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
3
States / cities
Los Angeles, California • Redondo Beach, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Sep 20, 2026, 7:22 PM EDT
Completed Phase 2 Interventional Results available

F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer

NCT00602043
View directory record Official record
Conditions
Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
F-18 16 alpha-fluoroestradiol, fludeoxyglucose F 18, positron emission tomography, computed tomography, laboratory biomarker analysis
Radiation · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 18, 2020 · Synced Sep 20, 2026, 7:22 PM EDT
Completed No phase listed Observational

Survival Study for Participants Treated With Ipilimumab-Nivolumab Combination Therapy

NCT03438279
View directory record Official record
Conditions
Melanoma
Interventions
Non-Interventional
Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 18, 2018 · Synced Sep 20, 2026, 7:22 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies

NCT05885555
View directory record Official record
Conditions
Primary Immune Thrombocytopenia (ITP)
Interventions
Ianalumab
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 20, 2026, 7:22 PM EDT
Completed No phase listed Observational

Setup Variation in the Supraclavicular Lymph Nodes Treatment in Breast Cancer Patients

NCT00658281
View directory record Official record
Conditions
Breast Cancer
Interventions
CBCT Scan, OBI KV Imaging
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2015 · Synced Sep 20, 2026, 7:22 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Same-Day Combination of VI Peel and Botox for Correction of Sun Damage, Fine Lines and Wrinkles

NCT05162300
View directory record Official record
Conditions
Photoaging, Wrinkle, Sun Damaged Skin
Interventions
Same Day Intervention of VI Peel (Procedure) and Botulinum Toxin (Drug)
Combination Product
Lead sponsor
Vitality Institute Medical Products
Industry
Eligibility
30 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rancho Mirage, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Sep 20, 2026, 7:22 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Morphea in Adults and Children (MAC) Cohort Study: A Morphea Registry and DNA Repository

NCT01808937
View directory record Official record
Conditions
Scleroderma, Localized, Morphea, Frontal Linear Scleroderma en Coup de Sabre, Scleroderma, Circumscribed, Scleroderma, Linear
Interventions
Morphea
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Up to 90 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 20, 2026, 7:22 PM EDT
Completed No phase listed Observational

A Study of Real-World Outcomes of Ribociclib in First-Line Treatment for Metastatic HR+/HER2- Breast Cancer

NCT07086196
View directory record Official record
Conditions
Metastatic HR+/HER2- Breast Cancer
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Sep 20, 2026, 7:22 PM EDT
Completed Phase 2 Interventional Results available

Docetaxel With Bevacizumab as First-Line Therapy in Treating Women With Stage IV Breast Cancer

NCT00217672
View directory record Official record
Conditions
Breast Cancer
Interventions
bevacizumab, Docetaxel
Biological · Drug
Lead sponsor
Translational Oncology Research International
Other
Eligibility
18 Years and older · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Sep 20, 2026, 7:22 PM EDT
Completed Phase 2 Interventional

Paclitaxel With or Without PSC 833 in Treating Patients With Metastatic Breast Cancer

NCT00002937
View directory record Official record
Conditions
Breast Cancer
Interventions
paclitaxel, valspodar
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2005
U.S. locations
3
States / cities
Duarte, California • Los Angeles, California • Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 5, 2010 · Synced Sep 20, 2026, 7:22 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Women With Breast Cancer That is Metastatic or Cannot be Treated With Surgery

NCT00015886
View directory record Official record
Conditions
Breast Cancer
Interventions
docetaxel, fluorouracil
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2009
U.S. locations
6
States / cities
Goldsboro, North Carolina • Greenville, North Carolina • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2018 · Synced Sep 20, 2026, 7:22 PM EDT
Completed Phase 3 Interventional

Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

NCT00028990
View directory record Official record
Conditions
Breast Cancer
Interventions
bevacizumab, Paclitaxel
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
722 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
28
States / cities
Mobile, Alabama • Scottsdale, Arizona • Jacksonville, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Sep 20, 2026, 7:22 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions

NCT04540900
View directory record Official record
Conditions
Skin Roughness, Wrinkle, Fine Lines, Skin Thickness
Interventions
KB301, Placebo
Biological · Other
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2029
U.S. locations
4
States / cities
Campbell, California • Newport Beach, California • Rancho Santa Margarita, California + 1 more
Source: ClinicalTrials.gov public record
Updated May 12, 2025 · Synced Sep 20, 2026, 7:22 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

NCT05374512
View directory record Official record
Conditions
Breast Cancer
Interventions
Dato-DXd, Paclitaxel, Nab-paclitaxel, Carboplatin, Capecitabine, Eribulin mesylate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
644 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
27
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 20, 2026, 7:22 PM EDT